2024-11-20 22:19:49
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
Health/ 2023-07-22
PolyActiva Announces Positive Phase IIa ...

- Primary and Secondary Efficacy Endpoints Met,Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patien...

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
Corporate/ 2023-07-24
Gracell Biotechnologies Doses First Pati...

SUZHOU,China and PALO ALTO,Calif.,Feb. 17,2022--Gracell Biotechnologies Inc. ("Gracell" or the "Company",NASDAQ: GRCL),a...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release